This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Onyx Shares Rise on Breast-Cancer Data

Onyx Pharmaceuticals (ONXX) said Wednesday that its cancer drug Nexavar extended progression-free survival in a mid-stage study of women with advanced breast cancer.

The announcement helped push Onyx shares up 29% to $37 in pre-market trading.

Nexavar, a pill, is currently marketed as a treatment for kidney and liver cancers. Onyx and its partner, the German drug firm Bayer, have been testing Nexavar in other types of cancer as well.

The phase II study announced Wednesday evaluated treatment with Nexavar and the oral chemotherapy drug Xeloda, marketed by Roche, compared to Xeloda plus placebo.

Women with advanced Her-2 negative breast cancer treated with the Nexavar-Xeloda combination demonstrated a lengthening of time before their cancer grew compared to woman treated with Xeloda alone.

Onyx said the results were statistically significant although details about the study were being withheld so that they could be presented later at a medical conference.

"Based on these encouraging data, Onyx and Bayer are evaluating various strategies for Nexavar in breast cancer," said Dr. Todd Yancey, vice president of clinical development at Onyx.

Onyx and Bayer are currently conducting other phase II studies of Nexavar in breast cancer.
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ONXX $0.00 0.00%
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs